Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD Overview On March 26, 2020, Bristol Myers Squibb announced that the United States Food and Drug Administration (FDA) approved Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS […]

The “coronavirus disease 2019” (COVID-19) is a potentially serious respiratory disease that was first reported in December 2019 in China. As of early March 2020, the illness had made its way to almost 70 locations, including the United States, and has affected more than 90,000 individuals worldwide. Please be aware that these figures are expected to increase on a weekly or even a daily basis.

The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. For this year’s campaign, MSAA is focusing on The Mind, Body, and MS Connection, addressing the integration of physical and emotional wellness strategies to improve MS symptom management and overall quality of life. MSAA invites the MS community to participate […]

The Multiple Sclerosis Association of America (MSAA), founded in 1970, is proud to recognize its 50th Anniversary in 2020 as a nonprofit organization dedicated to supporting the multiple sclerosis community and Improving Lives Today through vital services and support. MSAA would like to share several initiatives and events dedicated to commemorating this important milestone: To […]

To live with multiple sclerosis (MS) is to cope with the challenges it presents and to look forward to the promise of ongoing progress in understanding and managing the condition. This edition of “What’s New in MS Research” reflects that mix of obstacles and opportunities.

The Multiple Sclerosis Association of America (MSAA) is pleased to introduce our new logo and redesigned website homepage! As we enter our 50th year of dedicated service to the MS community, we are proud to share this important announcement about our new brand identity. While we are excited about our new look, please be assured […]

The Multiple Sclerosis Association of America (MSAA) is proud to announce the new Chairperson of the Healthcare Advisory Council for the organization. Dr. Carrie Hersh, a multiple sclerosis specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health – Las Vegas, has assumed the position. Dr. Hersh joined the faculty at the Cleveland Clinic […]

On December 5, 2019, the United States Food and Drug Administration (FDA) announced that they had approved the applications from three separate pharmaceutical companies for the first generic versions of Gilenya® (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

This edition of MSAA’s “What’s New in MS Research” provides highlights from this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Experts from throughout the world gathered in Stockholm, Sweden in mid-September to share and discuss the latest research into the causes, diagnosis, course, and treatment of multiple sclerosis.